###### Strengths and limitations of this study

-   The present network meta-analysis (NMA) integrated evidence from direct and indirect comparisons. We applied GRADE system to NMA-based GRADE working group to rate the quality of the evidence.

-   We comprehensively summarised all randomised-controlled trials (RCTs) of selenium supplements for Kashin-Beck disease.

-   Despite our exhaustive search, only 15 RCTs conducted in China were included in this review. Some trials may have been published in local journals that were missed in our search.

-   The overall quality of the evidence was low or very low. The surface under the cumulative ranking curve values may be misleading and should be considered jointly with the GRADE confidence in the estimates for each comparison.

Introduction {#s1}
============

Kashin-Beck disease (KBD) is an endemic, chronic, disabling degenerative disorder of peripheral joints and spine.[@R1] It is present primarily among people in southeast Siberia, north Korea and China.[@R3] KBD is prevalent in 377 counties of 14 provinces in China, with 0.64 million cases.[@R4] KBD occurs in childhood and includes alterations in the epiphysial plate and metaphysis. This leads to a variety of complications, such as bony deformity, joints enlargement, growth retardation and functional impairment in multiple joints, which is a significant human and social economically problem for all individuals involved. Moreover, KBD can also cause disruptive cartilage metabolism lipid peroxidation, and disturb the metabolism of selenium and sulfur.[@R5] Because of the incomplete ability of the cartilage to repair itself, only few therapies are available to treat KBD. For example, non-steroidal anti-inflammatory drugs,[@R7] sodium hyaluronate,[@R8] physical therapy[@R9] and chondroitin sulfate combined with glucosamine are an option.[@R10] Moreover, orthopaedists have demonstrated that surgery to repair joint defects is beneficial.[@R11]

Although the aetiology of KBD is multifactorial, one of the major environmental risk factors is selenium deficiency.[@R13] Since the 1970s, selenium was administered in several severely endemic regions. A meta-analysis study consisting of 5 randomised-controlled trials (RCTs) as well as 10 non-RCTs demonstrated benefits of selenium administration in preventing KBD in children.[@R14] Another systematic review suggested that sodium selenite (Se) was effective for the treatment of patients already affected with KBD.[@R15] Besides Se tablet, there are other selenium supplements used for treating KBD, including selenium salts (Se salt), selenium enriched yeast (Se yeast), combining sodium selenite and vitamin E (Se+VE) and combining sodium selenite and vitamin C (Se+VC). At the time of our review, there were few head-to-head comparisons of different types of selenium supplement for treatment of KBD. In light of the need for government policy-makers and clinical care workers to know the effects of a set of alternative options, a systematic review and network meta-analysis (NMA) was performed. This study aimed at comparing the effectiveness of administration of selenium in treating patients with KBD, and rank these selenium supplementations based on their performance.

Method {#s2}
======

In this study, a protocol was devised according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The protocol was registered on International prospective register of systematic reviews (PROSPERO), and the trial registration number was CRD42016051874.

Search strategy {#s2a}
---------------

We searched all the literature from 1 January 1966 to 31 March 2017. In our study, we used electronic databases, including EMBASE, MEDLINE, The Cochrane Database of Systematic Reviews, The Cochrane Central Register of Controlled Trials, The Chinese Biomedical Database, Chinese National Knowledge Infrastructure, Chinese Science and Technique Journals Database, and the Wan Fang database. Keywords used in our search criteria included KBD, big bone disease, Urov disease, endemic osteoarthritis, as well as selenium, sodium selenite and Se. Online [supplementary appendix box 1](#SP1){ref-type="supplementary-material"} presents the Ovid search strategy used. For identification of additional studies of interest, references from publications were manually screened.
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Eligibility criteria {#s2b}
--------------------

We included all RCTs that used Se tablet and other types of selenium supplements including Se salt, Se yeast, Se+VE and Se +VC for patients with KBD. The control groups included placebo or no treatment controls, or other active medicines. The diagnostic criteria used for KBD was based on the Diagnosis Criteria for Kashin-Beck Disease (GB16003-1995), which was developed by the National Health and Family Planning Commission of China.[@R16] We excluded the following studies: (1) studies with small sample sizes (numbers of patients \<20 in each treatment group); (2) preventive studies; (3) studies without available information of interest. The studies in which individuals with and without KBD were enrolled only if the therapeutic effect data could be extracted. Outcome of interest to this review was the rate of repair of metaphyseal lesions using X-ray film. Typically, repair was defined as being cured basically or improved significantly of metaphyseal lesions according to the latest judgement standard of X-ray for treatment effect of KBD.[@R17]

Data extraction and quality evaluation {#s2c}
--------------------------------------

Two authors (YL and DX) independently screened all citations identified by the searches. Full-text articles of potential studies were obtained and assessed according to the aforementioned inclusion criteria. The data extraction form included publication (first author, year of publication), demographics (sample size and age), interventions (dose, administration route and length of therapy), the follow-up period and outcomes. To determine the overall OR, data were extracted to the closest 12 months because this time point was reported in all included RCTs. Two reviewers independently evaluated the methodological quality of individual study according to the Cochrane risk-of-bias tool.[@R18] In our review, we applied the GRADE system to our NMA based on the GRADE working group.[@R19] The methods of rating the quality of direct comparison are the same for GRADE in traditional meta-analysis. Evidence was downgraded by one level from 'high quality' for significant (or by two levels for very significant), study limitations (risk of bias), indirect of evidence, inconsistency, imprecision of effects or potential bias in publication. The rating of quality of indirect estimates was based on the ratings of the two pairwise estimates that contributes to the indirect estimate of the comparison of interest. The lower rating score of direct comparisons comprises the confidence score of indirect comparisons. When direct and indirect evidences were available, the highest score was used as a quality score for NMA assessment.[@R19] In addition, we needed to consider the intransitivity among different groups and the inconsistency between direct comparison and indirect comparison. Furthermore, we used the GRADE profiler to help us create 'Summary of findings' tables. In case of a discrepancy, an additional experienced rater was consulted (JY).

Statistical analysis {#s2d}
--------------------

As the repair rate of metaphyseal lesions on X-ray film, the outcome of interest in this text, was a discontinuous statistics, we calculated the OR and its 95%CI as the effect estimates. The reason why ORs were used instead of risk ratios (RRs) was as follows: the inferential fallacies by using RR in indirect comparison offers the possibility for abuse regarding choice when outlining outcomes and confound the decision-making process in which both data sets are shown. ORs can overcome this misconception, and dependably interprets regarding treatment effect direction in indirect comparisons.[@R20] Initially, we performed standard pairwise meta-analyses for all available direct comparisons using a random effects model in RevMan V.5.3. Statistical heterogeneity of treatment effects across studies was assessed by the Cochrane Q test, and the extent of between-study heterogeneity was quantified by I^2^, which with a value \>50% indicates significant heterogeneity. Then, to estimate the efficiency of each intervention, a random effects model NMA was performed in STATA by conducting a network command and self-programmed STATA, which can be found at <http://www.mtm.uoi.gr>. We present the mean effect sizes for the network estimates (OR) along with their 95%CI and prediction intervals (PrI). The PrI shows the predicted parameter around estimated treatment effects in the future study.

To evaluate consistency within a network, a 'design-by-treatment' model was used, as performed by Higgins *et al*[@R18], by using the network meta command in STATA. This approach accounted for several causes of inconsistency, which may have occurred when studies with different designs (two-arm trials vs three-arm trials) give different results as well as disagreement between direct and indirect evidences.[@R21] In this study, the Χ^2^ test was used to determine any inconsistency within the network, and P\>0.05 indicated that the direct and indirect comparisons within the network were consistent.

We also estimated the ranking probabilities for all treatment methods at each possible rank. Rankings were obtained by the surface under the cumulative ranking curve (SUCRA) values as well as mean ranks. SUCRA could be presented as a percentage of effectiveness of a treatment method that would be ranked first without hesitation. To derive these SUCRA values, we used the ranking probabilities estimated from the mvmeta command.

Results {#s3}
=======

Study inclusion and characteristics {#s3a}
-----------------------------------

Initial searches yielded 1857 citations. Of these, 1816 duplicate or irrelevant records were excluded and full-text articles of the remaining 41 studies were retrieved for further assessment according to the inclusion criteria. A total of 15 studies[@R22] containing 2931 patient were included eventually in our meta-analysis ([figure 1](#F1){ref-type="fig"}). We excluded 26 trials for the reasons documented in the characteristics of excluded studies table (online [supplementary appendix table 1](#SP2){ref-type="supplementary-material"}).
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![Flow diagram of included study. RCT, randomised-controlled trial.](bmjopen-2017-017883f01){#F1}

A total of seven interventions were evaluated: Se, Se salt, Se yeast, Se+VE, Se+VC, VC and placebo. [Figure 2](#F2){ref-type="fig"} shows the network of all treatment comparisons included in this review. The age of participants ranges from 2 to 16 years, and the duration of follow-up varied from 6 to 36 months. The main characteristics of the included studies were similar, and the characteristics (eg, interventions dosage, route of administration, duration of treatment, the follow-up period and outcomes) are presented in online [supplementary appendix table 2](#SP2){ref-type="supplementary-material"}.

![Network of eligible comparisons for treatment efficacy network meta-analysis for Kashin-Beck disease. The width of lines is proportional to the number of studies compared in every pair of treatments, and the size of nodes is proportional to the total sample size of each treatment. Two-arm study, n=11; three-arm study, n=3 (Cui 1984,[@R25] Guo 1986,[@R28] Chen 2003[@R35]); four-arm study, n=1 (Zhou 1991[@R31]) Se, sodium selenite; Se salt, selenium salt; Se+VC,  the combination of sodium selenite with vitamin C; Se+VE,  the combination of sodium selenite with vitamin E; SE yeast, selenium enriched yeast; VC, vitamin C.](bmjopen-2017-017883f02){#F2}

Overall assessment for evidence quality {#s3b}
---------------------------------------

All included trials were reported to be RCTs. The quality of included studies was overall low. Study quality for each study can be seen in online [supplementary appendix table 3](#SP2){ref-type="supplementary-material"}. We downgraded this outcome from high to low or very low quality for possible bias, inconsistency or imprecision. Overall assessment for evidence quality was seen in [table 1](#T1){ref-type="table"}.

###### 

Quality ratings for comparison of different interventions

  Comparison            Quality of direct evidence   Quality of indirect evidence   Quality of network meta-analysis evidence
  --------------------- ---------------------------- ------------------------------ -------------------------------------------
  Se vs placebo         Low\*†                       Low\*‡                         Low\*†
  Se salt vs placebo    Low\*†                       Low\*‡                         Low\*†
  Se+VC vs placebo      Moderate\*                   Low\*‡                         Moderate\*
  Se+VE vs placebo      Very low\*†§                 Low\*‡                         Low\*‡
  Se yeast vs placebo   Moderate\*                   Low\*‡                         Moderate\*
  VC vs placebo         Moderate\*                   Low\*‡                         Moderate\*
  Se salt vs Se         --                           Very low\*§¶                   Very low\*§¶
  Se+VC vs Se           Moderate\*                   Low\*§                         Moderate\*
  Se+VE vs Se           --                           Very low\*§¶                   Very low\*§¶
  Se yeast vs Se        Moderate\*                   Very low\*§¶                   Moderate\*
  VC vs Se              Moderate\*                   Low\*¶                         Moderate\*
  Se+VC vs Se salt      Low\*‡                       Low\*¶                         Low\*¶
  Se+VE vs Se salt      --                           Very low\*§¶                   Very low\*§¶
  Se yeast vs Se salt   --                           Very low\*§¶                   Very low\*§¶
  VC vs Se salt         Low\*§                       Very low\*§¶                   Low\*,¶
  Se+VE vs Se+VC        --                           Very low\*§¶                   Very low\*§¶
  Se yeast vs Se+VC     --                           Very low\*§¶                   Very low\*§¶
  VC vs Se+VC           Moderate\*                   Very low\*§¶                   Moderate\*
  Se yeast vs Se+VE     --                           Very low\*§¶                   Very low\*§¶
  VC vs Se+VE           --                           Very low\*§¶                   Very low\*§¶
  VC vs Se yeast        --                           Very low\*§¶                   Very low\*§¶

\*Limitations (risk of bias).

†Inconsistency.

‡Inconsistency for indirect evidence: prediction intervals for treatment effect include effects that would have different interpretations.

¶Indirectness: no convincing evidence for the plausibility of the transitivity assumption.

§Imprecision.

Se, sodium selenite; Se salt, selenium salt; Se+VC, the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E; Se yeast, selenium enriched yeast; VC, vitamin C.

Intervention-control pairwise meta-analyses {#s3c}
-------------------------------------------

All RCTs reported repair rate of metaphyseal lesions on X-ray films. The individual study data used in the analyses were listed in online [supplementary appendix table 4](#SP2){ref-type="supplementary-material"}. Follow-up duration of included RCTs was varied. We extracted data to the nearest 12 months to estimate the overall OR. When compared with placebo, the pooled OR (random effects model) of X-ray improvement was in favour of Se (OR 5.0, 95% CI 3.21 to 7.78, P\<0.001, I^2^=70%), Se salt (OR 7.6, 95% CI 2.34 to 24.67, P=0.001), Se enriched yeast (OR 3.75, 95% CI 1.76 to 8.02, P=0.001) and Se +VE (OR 11.05, 95% CI 2.61 to 46.80, P=0.03, I^2^=60%), respectively, which indicated that repairing rate of metaphyseal lesions on X-ray films was significantly higher for these drugs than that for placebo (see online [supplementary appendix figure](#SP2){ref-type="supplementary-material"}). Summary of findings for each selenium supplement compared with placebo was seen in [table 2](#T2){ref-type="table"}. A few RCTs reported direct comparisons among active interventions. There were two RCTs that compared Se with VC; the pooled OR of two RCTs also showed that no significant difference exists (OR 1.15, 95% CI 0.51 to 2.63, P=0.93, I^2^=0%).[@R25] There was only one RCT for Se vs Se yeast,[@R28] Se vs Se +VC,[@R33] Se salt vs Se + VC,[@R33] Se salt vs VC,[@R33] respectively. OR of X-ray improvement was significantly higher in Se salt group compared with Se+VC (OR 6.00, 95% CI 1.81 to 19.93, P=0.003) and VC alone (OR 4.24, 95% CI 1.39 to 12.90, P=0.011). There were no significant differences noted in other active intervention comparisons (see [table 3](#T3){ref-type="table"}).

###### 

Summary of findings for each intervention in comparison to placebo

  ----------------------------------------------------------------------------------------------------------------------------------------
  Patient or population: children with Kashin-Beck disease\                                                                    
  Outcomes: improvement of metaphyseal lesions on X-ray\                                                                       
  Intervention: Se, Se salt, Se yeast, Se+VE, Se+VC, VC\                                                                       
  Comparison: placebo                                                                                                          
  ----------------------------------------------------------- ------------ ------------- ----------------- ------- ----------- -----------
  Se salt vs placebo                                          34 per 100   87 per 100\   OR 12.37\         86.0%   59\         ⨁⨁◯◯\
                                                                           (60 to 97)    (2.81 to 54.41)           (1 RCT)     Low †‡

  Se+VE vs placebo                                            45 per 100   90 per 100\   OR 10.72\         82.8%   145\        ⨁⨁◯◯\
                                                                           (72 to 97)    (3.14 to 36.57)           (2 RCTs)    Low†‡

  Se yeast vs placebo                                         38 per 100   78 per 100\   OR 5.81\          62.5%   120\        ⨁⨁⨁◯\
                                                                           (51 to 93)    (1.70 to 19.89)           (1 RCT)     Moderate†

  Se vs placebo                                               42 per 100   77 per 100\   OR 4.68\          52.5%   2427\       ⨁⨁◯◯\
                                                                           (69 to 84)    (2.99 to 7.34)            (11 RCTs)   Low†§

  Se+VC vs placebo                                            34 per 100   63 per 100\   OR 3.26\          35.7%   54\         ⨁⨁⨁◯\
                                                                           (38 to 83)    (1.14 to 9.28)            (1 RCT)     Moderate†

  VC vs placebo                                               34 per 100   61 per 100\   OR 3.05\          30.1%   124\        ⨁⨁⨁◯\
                                                                           (40 to 79)    (1.29 to 7.20)            (2 RCTs)    Moderate†
  ----------------------------------------------------------------------------------------------------------------------------------------

GRADE Working Group grades of evidence.

High quality: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

Very low quality: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

\*The repair rate in the intervention group (and its 95% CI) is based on the assumed rate in the comparison group and the relative effect of the intervention (and its 95% CI).

†Limitations (risk of bias): no studies described adequate methods regarding the sequence of randomisation and reported allocation concealment. Some studies did not use of a blinding method and intention-to-treat analysis.

‡Inconsistency: small sample size ora higher I² or both.

§Imprecision: the effects are large but the overall sample size is low.

RCT, randomised-controlled trial; Se, sodium  selenite; Se salt, selenium salt; Se+VC, the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E, Se yeast, selenium enriched yeast; SUCRA, surface under the cumulative ranking curve; VC, vitamin C.

###### 

Results of pairwise and network meta-analyses of repairing rate of metaphyseal lesions on X-ray films

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  OR (95% CI) \*   Placebo                      Se                      Se salt                Se+VC                   Se+VE                  Se yeast
  ---------------- ---------------------------- ----------------------- ---------------------- ----------------------- ---------------------- ----------------------
  Se               4.68 (2.99 to 7.34)^\*^\     --\                     --                     --                      --                     --
                   5.00 (3.21 to 7.78)          --                                                                                            

  Se salt          12.37 (2.81 to 54.41)^\*^\   2.64 (0.59 to 11.84)\   --                     --                      --                     --
                   7.60 (2.34 to 24.67)         --                                                                                            

  Se+VC            3.26 (1.14 to 9.28)^\*^\     0.70 (0.25 to 1.97)\    0.26 (0.06 to 1.20)\   --                      --                     --
                   1.27 (0.42 to 3.83)          1.30 (0.57 to 2.94)     0.17 (0.05 to 0.55)                                                   

  Se+VE            10.72 (3.14 to 36.57)^\*^\   2.29 (0.62 to 8.43)\    0.87 (0.13 to 5.93)\   3.29 (0.65 to 16.53)\   --                     --
                   11.05 (2.61 to 46.80)        --                      --                     --                                             

  Se yeast         5.81 (1.70 to 19.89)^\*^\    1.24 (0.36 to 4.25)\    0.47 (0.07 to 3.16)\   1.78 (0.37 to 8.66)\    0.54 (0.10 to 3.08)\   --
                   3.75 (1.76 to 8.02)          1.92 (0.90 to 4.00)     --                     --                      --                     

  VC               3.05 (1.29 to 7.20)^\*^\     0.65 (0.28 to 1.53)\    0.25 (0.06 to 1.06)\   0.94 (0.34 to 2.56)\    0.28 (0.06 to 1.27)\   0.52 (0.12 to 2.27)\
                   2.02 (0.98 to 4.17)          0.95 (0.51 to 1.79)     0.24 (0.08 to 0.72)    0.87 (0.38 to 1.96)     --                     --
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

In each cell, the first line represents the result of network meta-analyses, and the second row represents the result of pairwise meta-analyses.

\*ORs represent odds of repair in row treatment versus column treatment. ORs larger than 1 denote higher repair rate in row treatment than column treatment.

Se, sodium selenite; Se salt, selenium salt; Se+VC,  the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E; Se yeast, selenium enriched yeast; VC, vitamin C.

Results of NMAs and consistency test {#s3d}
------------------------------------

The pooled OR and 95% CI of X-ray improvement for active treatment compared with placebo was 4.68 (2.99 to 7.34) for Se, 12.37 (2.81 to 54.41) for Se salt, 5.81 (1.70 to 19.89) for Se enriched yeast, 10.72 (3.14 to 36.57) for Se+VE and 3.26 (1.14 to 9.28) for Se+VC, respectively, which indicated a significant difference in efficacy. For the comparison between active treatments, no significant differences were found. More details were presented in [table 3](#T3){ref-type="table"}. In [figure 3](#F3){ref-type="fig"}, we presented the OR for the network estimates along with 95% CI and PrI.

![Network estimates of mean ORs, their 95% CIs and 95% prediction intervals (red extensions), PrI, prediction intervals; Se, sodium selenite; Se salt, selenium salt; Se+VC, the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E; Se yeast, selenium enriched yeast; VC, vitamin C.](bmjopen-2017-017883f03){#F3}

There was no inconsistency between direct and indirect evidences according to the design-by-treatment interaction model (P=0.88), implying that direct and indirect evidences were mainly consistent ([figure 4](#F4){ref-type="fig"}). However, the results of the comparison of Se+VC and VC versus placebo showed some degree of inconsistency. Actually, the lower CI for X-ray improvement was nearly equal to 1 (1.13 for Se+VC and 1.27 for VC), showing a trend to coincide with direct results.

![Consistency test in the network meta-analysis. The X-axis is log OR, and the vertical line is 0. IF is the absolute inconsistency factor, meaning the logarithm of the ratio of ORs of direct and indirect evidences for each comparison loop. The absolute IF values and CIs are truncated at zero indicate no significant difference of inconsistency. IF, inconsistency  factor; Se, sodium  selenite; Se salt, selenium  salt; Se+VC, the combination of sodium selenite with vitamin C; Se yeast, selenium  enriched yeast; VC, vitamin C.](bmjopen-2017-017883f04){#F4}

[Table 2](#T2){ref-type="table"} and [figure 5](#F5){ref-type="fig"} displayed the distribution of probabilities for each treatment being ranked for their efficacy in KBD according to the SUCRA values.

![SUCRA for the cumulative probabilities. Se, sodium selenite; Se salt, selenium  salt; Se+VC, the combination of sodium selenite with vitamin C; Se+VE, the combination of sodium selenite with vitamin E; SUCRA, surface  under cumulative ranking; VC, vitamin C.](bmjopen-2017-017883f05){#F5}

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

Our NMA of all 15 available RCTs in 2931 patients with KBD showed that all five kinds of selenium supplementation (including Se, Se salt, Se enriched yeast, Se+VE, Se+VC) were superior to placebo/no treatment in repairing metaphyseal lesions. There was uncertainty around the difference between two active treatments. However, the probabilistic ranking of interventions showed that Se salt was ranked the most effective, followed by Se+VE, Se enriched yeast, Se and then Se+VC.

Relation to other studies {#s4b}
-------------------------

Studies have proposed that a deficiency in selenium is key in disposing target cells, such as chondrocytes, to oxidative stress.[@R37] In most highly endemic area, the level of total soil selenium concentrations is typically low. In a previous study, it was demonstrated that in endemic regions, selenium concentrations in water, soil, cereal and corn were reduced compared with regions without high rates of KBD.[@R38] Furthermore, the majority of individuals who live in areas with KBD have a low selenium nutritive status, as is indicated by the low levels of selenium in their serum, red blood cell, urine and hair.

The effectiveness of various methods of selenium supplementation for children has been demonstrated by many studies including Se salt,[@R39] Se enriched yeast,[@R28] oral sodium selenite tablet,[@R17] spraying Se on crops[@R40] and Se enriched fertiliser.[@R41] Selenium supplementation was related to a reduced KBD prevalence, along with an increased selenium content in the hair of individuals who live in areas with KBD. It was reported that the incidence of radiographic evidence of metaphysical lesions of the hands was 44.8% in 1990 at Cuimu town of the Shaanxi province in children aged 7--12 years. After implementation of comprehensive prevention measures of KBD, especially using Se salt, the incidence these X-ray findings decreased to 0.3% in 2010.[@R42] The low incidence of KBD also may explain why there has not been any studies about Se treatment for KBD published in recent years.

Se salt was produced as follows: a total of 0.833 g sodium selenite powder was added to 50 kg source salt and expanded to 1:60 000 of Se salt. Although administration of Se tablet is effective for prevention and treatment of KBD in children,[@R16] it is very difficult for many children who reside in endemic areas to adhere to any type of long-term medication. However, salt is a necessary part of daily life and food intake. The compliance can be more effectively guaranteed. A limitation to the findings about Se salt is that due to the difficulty of carrying out a RCT comparing Se salt with placebo or other active drugs, only one RCT has been done.[@R33] However, one meta-analysis involving 11 non-RCTs (2652 participants) also showed that supplement Se salt was effective for preventing and treatment for KBD in children.[@R39] Since Se salt is the most economical way for low-income families, it is anticipated that continuous use of Se salt and other comprehensive prevention approaches could be beneficial in eliminating KBD cartilage damages in children.[@R43]

Despite the evidence in our meta-analysis, there remains some controversy around selenium supplementation in relationship with iodine deficiency. In a previous study that was performed in the Tibet area, Moreno-Reyes *et al* did not find a relation between KBD ad selenium deficiency, whereas they did identify iodine deficiency as a risk factor.[@R44] Similarly, the only RCT[@R34] published in English in our review showed only one case of improvements in X-ray in sodium selenite group. The above studies should, however, be interpreted with caution. These studies were all performed in the Tibet area where selenium and iodine are both deficient in the diet. Moreover, both selenium and iodine deficiency are risk factors of KBD.[@R37] Previous studies have shown growth retardation in rats that were fed a diet containing low selenium levels.[@R45] In addition, impaired development of the bone was demonstrated when rats were fed a iodine-deficient diet.[@R46] Supplementation with selenium may not counterbalance the negative effects of long-term iodine deficiency. Thus, it does not seem very likely that KBD has only one cause. Additional factors (both genetic and environmental) may be a protective or show disease acceleration.

Methodological quality of included trials {#s4c}
-----------------------------------------

Overall, the methodological quality of the included trails was low. In all the included trials, methods of randomisation and allocation concealment were not presented. In eight trials, double blinding was described, whereas specifics of the methods of blinding were described in three trials. Withdrawal rates of participants were \<20% in eight trails. Only six trials performed intention-to-treat analysis.

After evaluation, we downgraded the evidence quality of primary outcomes from high to low or very low because of the high risk of bias due to unclear sequence generation and allocation concealment. Moreover, we observed very small sample sizes in several trials combined with higher levels of heterogeneity that showed significant inconsistency between trials.

Strengths and weaknesses {#s4d}
------------------------

In the current NMA, evidence was integrated from both direct and indirect comparisons. The literature search strategy was extensive, and it was unlikely that relevant trials were missed. The selection of trials as well as the extraction of data and quality assessments were performed by two investigators to minimise bias and transcription errors. In this NMA, we applied the GRADE system to NMAs based on the GRADE working group to rate the quality of the evidence.

Although the results are promising, this study has several limitations. First, the length of follow-up varied greatly, and varied from 6 to 36 months. However, follow-up period of most studies is concentrated in 12 months. Therefore, the data in our review were extracted to the nearest 12 months. Even so, the best beneficial duration of therapy period remains unclear for KBD. When compared with other RCTs in osteoarthritis, 36 months of therapy might be appropriate for detecting X-ray-related alterations of KBD. Second, the sample size of the RCTs included in our NMA was limited. Third, despite our extensive research, we were only able to include 15 RCTs in our NMA that were performed in China. Apart from China, both North Korea and Russia have a high KBD incidence, and it is likely that in our search, trials that were published in local journals may have been missed. Finally, in this study, the heterogeneity was relatively high that may be explained by a lack of allocation concealment, limited number of samples and alterations between selenium preparations. Similar as with heterogeneity between trials, inconsistency between direct and indirect comparisons was close to zero. Clinically relevant inconsistency cannot be ruled out; therefore, there is no indication that clinical characteristics of enrolled subjects or additional features of the trial confounded indirect comparisons.

Conclusions {#s5}
===========

Implications for clinical practice {#s5a}
----------------------------------

Based on the current NMA, all types of Se supplementation were of higher efficiency compared with the placebo in treating KBD in children. Ranking on efficacy indicated that Se salt was highest, followed by Se+VE, Se enriched yeast, Se, Se+VC, VC and placebo/no treatment. Since the overall assessment quality was relatively low (or very low), the SUCRA values may be misleading and should be considered jointly with the GRADE confidence in the estimates for each comparison. Evidence quality is insufficient to draw a conclusion about what method of selenium supplementation is most effective. Se salt can be an economical and convenient strategy for controlling KBD in endemic areas. However, selenium overdose is toxic. Therefore, suitable dosages should be strictly controlled and content of selenium should be closely monitored to prevent detrimental health-related issues.

Implications for research {#s5b}
-------------------------

Since KBD among children has almost disappeared, it is highly unlikely that upcoming trials involve RCT to demonstrate the clinically relevant benefit of any selenium supplementation for children with KBD. Currently, no effective therapy exists to correct KBD-related cartilage damage in adults. Novel approaches, including gene therapy and tissue engineering, may become a potential treatment strategy that can be used for treating KBD-related cartilage damages.
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